Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, January 29 - Friday, February 2, 2024), and click each link to read and watch anything you may have missed.
1.) Oteseconazole outperforms fluconazole in treating severe vulvovaginal candidiasis
A phase 3 trial demonstrated that oteseconazole (VIVJOA; Mycovia Pharmaceuticals) capsules exhibit improved therapeutic and mycological cure rates to fluconazole for treating severe vulvovaginal candidiasis.
2.) How monoclonal antibodies revolutionize sexual health
Explore the potential of monoclonal antibodies for contraception and sexually transmitted infection prevention, providing a comprehensive review of their safety, efficacy, and pharmacokinetics.
3.) Two-dose HPV vaccination postpartum shows efficacy
A recent study revealed a 2-dose regimen of human papillomavirus vaccination in postpartum individuals is as effective as a 3-dose approach, providing valuable insights into optimizing vaccination strategies against the virus.
4.) The Guardians app shows efficacy for reducing perinatal depression
Preliminary findings suggest The Guardians mobile app, blending gaming and behavioral activation techniques, could be a solution for alleviating perinatal depression among pregnant women.
5.) Dexmedetomidine found effective for reducing postpartum depression risk
A recent study revealed that early postpartum administration of dexmedetomidine significantly reduces the risk of postpartum depression among women with prenatal depression.